case_images: PMC11060151_01
case_images: PMC11060151_02
case_images: PMC11060151_03
case_images: PMC11060151_04
case_images: PMC11060151_05
case_images: Patient 5 (detailed under "breakthrough disease" in Supplementary material S3), 6 months post-initiation of rituximab treatment, the patient manifested an attack, encompassing both TM and encephalopathy, with a concurrent CD19+ B-cell count of 3%. MRI assessments during this episode included Sagittal T1-post contrast (A), Axial T2 (B), and Sagittal STIR (C) of the spine.
case_images: fneur-15-1352779-g001.jpg
case_images: PMC11060151_05_fneur-15-1352779-g001.jpg
case_images: fig1
case_images: Imaging techniques, including MRI of the brain, spine, optic orbits, and computed tomography (CT) scans of the spine and brain, were employed to track disease progression and evaluate treatment efficacy (Figure 1).
case_images: PMC11060151_06
case_images: PMC11060151_07
case_images: PMC11060151_08
case_images: PMC11060151_09